| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -222,796 | -141,230 |
| Stock-based compensation expense | 27,100 | 17,839 |
| Non-cash lease expense | 203 | 134 |
| Net amortization of premiums and discounts on marketable securities | 7,752 | 5,323 |
| Amortization of debt issuance costs and discount | 543 | 364 |
| Unrealized foreign exchange gain and loss | - | -26 |
| Loss on extinguishment of loan payable | -1,557 | - |
| Fair value change in warrant liability | -194 | 206 |
| Prepaid expenses and other assets | -10,593 | -5,104 |
| Accounts payable | 11,379 | 4,203 |
| Accrued expenses and other current liabilities | -3,500 | 2,908 |
| Operating lease liability | -214 | -141 |
| Net cash used in operating activities | -183,081 | -115,910 |
| Purchase of short-term and long-term marketable securities | 732,473 | 658,977 |
| Proceeds from maturities of short-term marketable securities | 386,411 | 256,134 |
| Net cash (used in) investing activities | -346,062 | -402,843 |
| Proceeds from the exercise of stock options | 13,742 | 10,371 |
| Proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases | 458 | 458 |
| Proceeds from the issuance of common stock and pre-funded warrants in a follow-on public offering | 378,350 | 378,350 |
| Proceeds from the issuance of common stock pursuant to the atm offering | 10,361 | 10,361 |
| Repayment of loan payable | 37,398 | - |
| Payment of debt and equity issuance costs | 576 | 576 |
| Net cash provided by financing activities | 364,937 | 398,964 |
| Net (decrease) increase in cash and cash equivalents | -164,206 | -119,789 |
| Cash and cash equivalents at beginning of period | 340,238 | - |
| Cash and cash equivalents at end of period | 176,032 | - |
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)